Biotech Archives - Page 127 of 795

HeartCore Enterprises, Inc. (NASDAQ:HTCR) ("HeartCore" or "the Company"), a leading enterprise software and consulting services company based in Tokyo, has signed a deal to implement its Contents Management System

HTCR

4 minute read

Milestone Scientific CEO Provides Letter To Shareholders; Provides Reimbursement Update For CompuFlo By Commercial Payors And Medicare

By Benzinga Newsdesk

January 16, 9:42 AM

Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided the following letter to shareholders from the Company's

MLSS

3 minute read

Amprius Broadens Product Portfolio With New Commercially Available Silicon Anode Battery Platform SiCore

By Benzinga Newsdesk

January 16, 9:37 AM

Complementary to the Silicon Nanowire Platform (Under the New Product Platform SiMaxxTM), the New SiCoreTM Platform Offers up to 400Wh/kg and as many as 1,200 CyclesAmprius Technologies, Inc. ("Amprius" or the "Company")

AMPX

1 minute read

Lineage Cell Therapeutics, Inc. Announces RG6501 Phase 1/2a Results Will Be Featured At 2024 Angiogenesis Exudation And Degeneration Meeting In Presentation By Allen Ho, MD, FACS, FASRS

By Benzinga Newsdesk

January 16, 9:23 AM

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results showing retinal structure

LCTX

2 minute read

Solid Biosciences Granted FDA Orphan Drug Designation For Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003; Patient Dosing Expected To Begin Mid-To-Late Q1 2024

By Benzinga Newsdesk

January 16, 9:08 AM

– Patient dosing expected to begin mid-to-late Q1 2024 – CHARLESTOWN, Mass., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing precision genetic medicines for

SLDB

3 minute read

Biora Therapeutics Provides Guidance On Anticipated Milestones During 2024; Says We Begin 2024 In The Clinic With Our Phase 1 Study For BT-600, Which Will Be A Major De-Risking Step In The Development Of Our NaviCap Platform

By Benzinga Newsdesk

January 16, 9:02 AM

Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today provided guidance on anticipated milestones during 2024. "In 2023, we completed the transformation of

BIOR

2 minute read

PacBio Announces New Nanobind PanDNA Kit Enabling HiFi Optimized DNA Extraction Solutions

By Benzinga Newsdesk

January 15, 7:28 PM

Existing HT CBB Kit Enables High-Throughput Extraction of HMW DNA Tailored for HiFi With an Updated Workflow for Animal Blood and BacteriaMENLO PARK, Calif., Jan. 15, 2024 /PRNewswire/ -- PacBio (NASDAQ:PACB), a

PACB

2 minute read

Liver Disease Player 89Bio Downgraded: Analyst Sees Short-Term Uncertainties In Fatty Liver Drug Development

By Vandana Singh

January 12, 3:41 PM

89Bio's journey in the clinical-stage biopharmaceutical space. RBC Capital Markets downgrades with insights on FGF21 drugs, pegozafermin, and 2024 uncertainties.

ETNB